<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03069365</url>
  </required_header>
  <id_info>
    <org_study_id>M16-127</org_study_id>
    <secondary_id>2016-004182-60</secondary_id>
    <nct_id>NCT03069365</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment ( Expedition-5 )</brief_title>
  <acronym>Expedition-5</acronym>
  <official_title>A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Renally-Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (EXPEDITION-5)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 3b, open-label, non-randomized study will evaluate the efficacy and safety of
      Glecaprevir/Pibrentasvir (GLE/PIB) for 8, 12, or 16 weeks in in participants with chronic
      hepatitis C virus (HCV) genotype (GT) 1 - 6 infection with or without compensated liver
      cirrhosis and with chronic renal impairment in both HCV treatment-naïve and prior
      treatment-experienced participants.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 28, 2017</start_date>
  <completion_date type="Anticipated">June 5, 2018</completion_date>
  <primary_completion_date type="Actual">February 16, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with sustained virologic response 12 weeks post dosing (SVR12)</measure>
    <time_frame>12 weeks after last dose of study drug</time_frame>
    <description>SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) levels less than the lower limit of quantitation (LLOQ) (less than 15 IU/mL) 12 weeks after the last actual dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with post-treatment HCV virologic relapse</measure>
    <time_frame>Up to 28 weeks (12 weeks after last dose of study drug)</time_frame>
    <description>Post-treatment virologic failure (Relapse) is defined as:
- Confirmed HCV RNA greater than or equal to LLOQ (defined as confirmed HCV RNA greater than or equal to LLOQ between end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment as planned with HCV RNA less than LLOQ at the end of treatment; excluding participants who have been shown to be re-infected), for participants who completed treatment (defined as study drug duration ≥ 77 days, ≥ 105 days and 103 days for participants allocated to the 8, 12 and 16 week durations, respectively).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HCV on-treatment virologic failure</measure>
    <time_frame>Up to 16 weeks (treatment arm specific)</time_frame>
    <description>HCV on-treatment virologic failure defined as:
Confirmed increase from nadir in HCV RNA defined as confirmed increase of &gt; 1 log10 IU/mL above nadir during treatment; or
Confirmed HCV RNA greater than or equal to 100 IU/mL after HCV RNA less than LLOQ during study drug treatment; or
HCV RNA ≥ LLOQ at the end of treatment with at least 6 weeks of treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Hepatitis C Virus (HCV)</condition>
  <arm_group>
    <arm_group_label>Arm B: GLE/PIB for 12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B: HCV GT1, 2, 4 - 6 participants with cirrhosis who are TN or TE and HCV GT 3 participants with cirrhosis who are TN treated with GLE/PIB 300 mg/120 mg QD for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: GLE/PIB for 16 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm C: All HCV GT3 participants who are TE will be treated with GLE/PIB 300 mg/120 mg QD for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A: GLE/PIB for 8 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A: Hepatitis C Virus (HCV) Genotype (GT)1, 2, 4 - 6 participants without cirrhosis who are treatment naïve (TN) or treatment experienced (TE) and HCV GT 3 participants without cirrhosis who are TN treated with Glecaprevir (GLE)/Pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glecaprevir/Pibrentasvir</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>Arm A: GLE/PIB for 8 weeks</arm_group_label>
    <arm_group_label>Arm B: GLE/PIB for 12 weeks</arm_group_label>
    <arm_group_label>Arm C: GLE/PIB for 16 weeks</arm_group_label>
    <other_name>ABT-493/ABT-530</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant has a positive anti-hepatitis C virus (HCV) antibody (Ab) and plasma HCV
             ribonucleic acid (RNA) greater than or equal to 1000 IU/mL at Screening Visit.

          -  Participant has an estimated glomerular filtration rate (eGFR) less than 45mL/min/1.73
             m^2

          -  Cirrhotic participants only: absence of hepatocellular carcinoma (HCC)

        Exclusion Criteria:

          -  Current HBV or human immunodeficiency virus (HIV) infection on screening tests,
             defined as:

          -  Positive test result at screening for hepatitis B surface antigen (HBsAg) or

          -  HBV DNA less than lower limit of quantification (LLOQ) in participants with isolated
             positive anti-HBc (i.e., negative HBsAg and Anti-HBs), or

          -  Positive anti-HIV antibody (Ab).

          -  Clinical history of acute renal failure in the 3 months prior to screening.

          -  Clinically significant abnormalities or co-morbidities, or recent (within 6 months
             prior to study drug administration) alcohol or drug abuse that could preclude
             adherence to the protocol in the opinion of the investigator.

          -  Receipt of any investigational or commercially available direct acting anti-HCV agents
             other than sofosbuvir.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntington Medical Foundation</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa General Medical Group</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Louisiana Nephrology</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Univ Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-5502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107-4414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TX Liver Inst, Americ Res Corp</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zeidler Ledcor Centre</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver ID Research and Care</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(GIRI) GI Research Institute</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wurttemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med Hochschule Hanover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Johannes Gutenberg</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens Laiko</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gen Univ Hosp Alexandroupolis</name>
      <address>
        <city>Alexandroupolis</city>
        <zip>68100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genl Hosp Athens, Evangelismos</name>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bioclinic Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54622</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico S.Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico A. Gemelli</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Paolo Giaccone</name>
      <address>
        <city>Palermo</city>
        <state>Sicilia</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Uni Giovanni e Ruggi</name>
      <address>
        <city>Salerno</city>
        <zip>84100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Seoul Hospi</name>
      <address>
        <city>Seongdong-gu</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HepID - Diagnostyka I Terapia</name>
      <address>
        <city>Lublin</city>
        <state>Lubelskie</state>
        <zip>20-884</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczn</name>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny ZOZ</name>
      <address>
        <city>Warsaw</city>
        <zip>01-201</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Caribbean Healthcare System</name>
      <address>
        <city>San Juan</city>
        <zip>00921-3201</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico, School of Medicine</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul Nat. de Boli Infectioase</name>
      <address>
        <city>Bucuresti</city>
        <zip>010825</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic Fundeni Institute</name>
      <address>
        <city>Bucuresti</city>
        <zip>030463</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional de Malaga</name>
      <address>
        <city>Málaga</city>
        <state>Malaga</state>
        <zip>29009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Parc de Salut del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Doce de</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Uni</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2017</study_first_submitted>
  <study_first_submitted_qc>February 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2017</study_first_posted>
  <last_update_submitted>April 28, 2018</last_update_submitted>
  <last_update_submitted_qc>April 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatitis C Virus</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Glecaprevir</keyword>
  <keyword>Pibrentasvir</keyword>
  <keyword>Hepatitis C Virus Genotype</keyword>
  <keyword>compensated cirrhosis</keyword>
  <keyword>non-cirrhotic</keyword>
  <keyword>interferon (IFN)</keyword>
  <keyword>treatment naïve</keyword>
  <keyword>sofosbuvir (SOF)</keyword>
  <keyword>pegylated interferon (pegIFN)</keyword>
  <keyword>ribavirin (RBV)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

